281 related articles for article (PubMed ID: 26172874)
1. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.
Miethke AG; Zhang W; Simmons J; Taylor AE; Shi T; Shanmukhappa SK; Karns R; White S; Jegga AG; Lages CS; Nkinin S; Keller BT; Setchell KD
Hepatology; 2016 Feb; 63(2):512-23. PubMed ID: 26172874
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
3. Toxic bile and sclerosing cholangitis: Is there a role for pharmacological interruption of the bile acid enterohepatic circulation?
Dawson PA
Hepatology; 2016 Feb; 63(2):363-4. PubMed ID: 26600416
[No Abstract] [Full Text] [Related]
4. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435.
Bhat BG; Rapp SR; Beaudry JA; Napawan N; Butteiger DN; Hall KA; Null CL; Luo Y; Keller BT
J Lipid Res; 2003 Sep; 44(9):1614-21. PubMed ID: 12810816
[TBL] [Abstract][Full Text] [Related]
7. Colesevelam attenuates cholestatic liver and bile duct injury in
Fuchs CD; Paumgartner G; Mlitz V; Kunczer V; Halilbasic E; Leditznig N; Wahlström A; Ståhlman M; Thüringer A; Kashofer K; Stojakovic T; Marschall HU; Trauner M
Gut; 2018 Sep; 67(9):1683-1691. PubMed ID: 29636383
[TBL] [Abstract][Full Text] [Related]
8. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
9. SC-435, an ileal apical sodium-codependent bile acid transporter inhibitor alters mRNA levels and enzyme activities of selected genes involved in hepatic cholesterol and lipoprotein metabolism in guinea pigs.
West KL; McGrane M; Odom D; Keller B; Fernandez ML
J Nutr Biochem; 2005 Dec; 16(12):722-8. PubMed ID: 16169202
[TBL] [Abstract][Full Text] [Related]
10. Role of hepatic transporters in prevention of bile acid toxicity after partial hepatectomy in mice.
Csanaky IL; Aleksunes LM; Tanaka Y; Klaassen CD
Am J Physiol Gastrointest Liver Physiol; 2009 Sep; 297(3):G419-33. PubMed ID: 19497955
[TBL] [Abstract][Full Text] [Related]
11. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2
Fuchs CD; Dixon ED; Hendrikx T; Mlitz V; Wahlström A; Ståhlman M; Scharnagl H; Stojakovic T; Binder CJ; Marschall HU; Trauner M
Hepatol Commun; 2022 Sep; 6(9):2368-2378. PubMed ID: 35691019
[TBL] [Abstract][Full Text] [Related]
12. Apical sodium-dependent bile acid transporter upregulation is associated with necrotizing enterocolitis.
Halpern MD; Weitkamp JH; Mount Patrick SK; Dobrenen HJ; Khailova L; Correa H; Dvorak B
Am J Physiol Gastrointest Liver Physiol; 2010 Sep; 299(3):G623-31. PubMed ID: 20616306
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis.
Ghallab A; González D; Strängberg E; Hofmann U; Myllys M; Hassan R; Hobloss Z; Brackhagen L; Begher-Tibbe B; Duda JC; Drenda C; Kappenberg F; Reinders J; Friebel A; Vucur M; Turajski M; Seddek AL; Abbas T; Abdelmageed N; Morad SAF; Morad W; Hamdy A; Albrecht W; Kittana N; Assali M; Vartak N; van Thriel C; Sous A; Nell P; Villar-Fernandez M; Cadenas C; Genc E; Marchan R; Luedde T; Åkerblad P; Mattsson J; Marschall HU; Hoehme S; Stirnimann G; Schwab M; Boor P; Amann K; Schmitz J; Bräsen JH; Rahnenführer J; Edlund K; Karpen SJ; Simbrunner B; Reiberger T; Mandorfer M; Trauner M; Dawson PA; Lindström E; Hengstler JG
J Hepatol; 2024 Feb; 80(2):268-281. PubMed ID: 37939855
[TBL] [Abstract][Full Text] [Related]
14. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the
Fuchs CD; Sroda N; Scharnagl H; Gupta R; Minto W; Stojakovic T; Liles JT; Budas G; Hollenback D; Trauner M
JHEP Rep; 2023 Nov; 5(11):100874. PubMed ID: 37841639
[TBL] [Abstract][Full Text] [Related]
15. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.
Kunst RF; de Waart DR; Wolters F; Duijst S; Vogels EW; Bolt I; Verheij J; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
JHEP Rep; 2022 Nov; 4(11):100573. PubMed ID: 36160754
[TBL] [Abstract][Full Text] [Related]
16. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M
Gastroenterology; 2004 Jul; 127(1):261-74. PubMed ID: 15236191
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.
Tiessen RG; Kennedy CA; Keller BT; Levin N; Acevedo L; Gedulin B; van Vliet AA; Dorenbaum A; Palmer M
BMC Gastroenterol; 2018 Jan; 18(1):3. PubMed ID: 29304731
[TBL] [Abstract][Full Text] [Related]
18. Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice.
Baghdasaryan A; Fickert P; Fuchsbichler A; Silbert D; Gumhold J; Hörl G; Langner C; Moustafa T; Halilbasic E; Claudel T; Trauner M
Liver Int; 2008 Aug; 28(7):948-58. PubMed ID: 18410282
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 2 Promotes Hepatic Regulatory T Cell Responses and Protects From Biliary Fibrosis in Murine Sclerosing Cholangitis.
Taylor AE; Carey AN; Kudira R; Lages CS; Shi T; Lam S; Karns R; Simmons J; Shanmukhappa K; Almanan M; Chougnet CA; Miethke AG
Hepatology; 2018 Nov; 68(5):1905-1921. PubMed ID: 29698570
[TBL] [Abstract][Full Text] [Related]
20. Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.
Wu N; Meng F; Zhou T; Han Y; Kennedy L; Venter J; Francis H; DeMorrow S; Onori P; Invernizzi P; Bernuzzi F; Mancinelli R; Gaudio E; Franchitto A; Glaser S; Alpini G
FASEB J; 2017 Oct; 31(10):4305-4324. PubMed ID: 28634212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
